14228-23-0

Basic information

• Product Name: 2-(4-Pyridinyl)-4-quinolinecarboxylic acid
• Synonyms: 2-(4-pyridinyl)-4-quinolinecarboxylicaci;2-(4-pyridyl)-cinchoninicaci;2-(4-pyridyl)cinchoninicacid;2-(4-pyridyl)cinchoninsaeure;2-(4-Pyridinyl)-4-quinolinecarboxylic acid;2-pyridin-4-ylquinoline-4-carboxylic acid(SALTDATA: FREE);2-(4-pyridyl)-4-quinolinecarboxylic acid;2-(4-Pyridyl)cinchoninsaeure [German]
• CAS NO: 14228-23-0
• Molecular Formula: C₁₅H₁₀N₂O₂
• Molecular Weight: 250.25
• Mol File: 14228-23-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 468.4°Cat760mmHg
• Flash Point: 237.1°C
• Appearance: /
• Density: 1.332g/cm³
• Vapor Pressure: 1.42E-09mmHg at 25°C
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-(4-Pyridinyl)-4-quinolinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Pyridinyl)-4-quinolinecarboxylic acid(14228-23-0)
• EPA Substance Registry System: 2-(4-Pyridinyl)-4-quinolinecarboxylic acid(14228-23-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 14228-23-0(Hazardous Substances Data)

Usage

General Description

2-(4-Pyridinyl)-4-quinolinecarboxylic acid, also known as quinaldinic acid, is a chemical compound with the molecular formula C15H10N2O2. It is a derivative of quinoline and contains a pyridine ring. Quinaldinic acid has been studied for its potential neurotoxic effects and its role in the pathogenesis of neurodegenerative diseases such as Alzheimer's and Huntington's. It has also been implicated in the progression of inflammatory diseases such as multiple sclerosis. Quinaldinic acid is a potent activator of the NMDA receptor and has been shown to induce oxidative stress and neuroinflammation in various experimental models. 2-(4-Pyridinyl)-4-quinolinecarboxylic acid has attracted attention as a potential target for therapeutic interventions in neurodegenerative and inflammatory conditions.

InChI:InChI=1/C15H10N2O2/c18-15(19)12-9-14(10-5-7-16-8-6-10)17-13-4-2-1-3-11(12)13/h1-9H,(H,18,19)/p-1

Upstream product

• 1122-54-9 methyl (4-pyridyl) ketone 
• 91-56-5 indole-2,3-dione 
• 98-86-2 acetophenone 

Downstream Products

• 1351929-56-0 N-(4-(hydroxymethyl)phenyl)-2-(pyridin-4-yl)quinoline-4-carboxamide 
• 1351929-55-9 N-(4-(methylamino)phenyl)-2-(pyridin-4-yl)quinoline-4-carboxamide 
• 1144460-63-8 N-(4-hydroxyphenyl)-2-(pyridin-4-yl)quinoline-4-carboxamide 
• 863670-33-1 2-(pyridin-4-yl)-N-p-tolylquinoline-4-carboxamide 
• 1351929-43-5 N-(4-(dimethylamino)phenyl)-2-(pyridin-4-yl)quinoline-4-carboxamide 
• 879921-23-0 N-(4-methoxyphenyl)-2-(pyridin-4-yl)quinoline-4-carboxamide 
• 879921-41-2 N-phenyl-2-(pyridin-4-yl)quinoline-4-carboxamide 
• 1165797-18-1 tert-butyl {[trans-4-({[(2-(pyridin-4-yl)quinolin-4-yl)carbonyl]amino}methyl)cyclohexyl]methyl}carbamate 

Relevant articles and documents

Synthesis, structure evaluation, spectroscopic and antibacterial investigation of metal complexes with 2-(pyridin-4-yl)quinoline-4-carboxylic acid

Four metal complexes based on quinoline carboxylate ligand from 2-(pyridin-4-yl)quinoline-4-carboxylic acid (HL), {[ML2(H2O)2]·2H2O}n (M = MnII, 1; M = CoII, 2; M = CdII, 3) and {[Ag2L2(H2O)2]·3H2O}n (4) have been synthesized under hydrothermal conditions. Their structures were determined by elemental analyses, IR spectra, and further characterized by single-crystal X-ray diffraction analysis. Complexes 1-3 feature a 1D chain structure which is further linked together to construct the 3D supramolecular network through hydrogen bonds. Complex 4 exhibits a 3D configuration. The fluorescent behavior and antibacterial activities of these compounds have been investigated.

Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats

Inhibition of acetyl-CoA carboxylases has the potential for modulating long chain fatty acid biosynthesis and mitochondrial fatty acid oxidation. Hybridization of weak inhibitors of ACC2 provided a novel, moderately potent but lipophilic series. Optimization led to compounds 33 and 37, which exhibit potent inhibition of human ACC2, 10-fold selectivity over inhibition of human ACC1, good physical and in vitro ADME properties and good bioavailability. X-ray crystallography has shown this series binding in the CT-domain of ACC2 and revealed two key hydrogen bonding interactions. Both 33 and 37 lower levels of hepatic malonyl-CoA in vivo in obese Zucker rats.

NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087

The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for th eir therapeutic use, particularly in the treatments of obesity and diabetes mellitus.